Myasthenia gravis epidemiology and demographics

Jump to navigation Jump to search

Myasthenia gravis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myasthenia Gravis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myasthenia gravis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myasthenia gravis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myasthenia gravis epidemiology and demographics

CDC on Myasthenia gravis epidemiology and demographics

Myasthenia gravis epidemiology and demographics in the news

Blogs on Myasthenia gravis epidemiology and demographics

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Myasthenia gravis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The incidence of Myasthenia gravis is approximately 7-23 new cases per year. The prevalence of Myasthenia gravis is approximately 70-320 per million and increasing since 20th century. The age of onset in Myasthenia gravis follows a bimodal distribution. The early type (before age of 50) is female predominant and the late type (after age of 60) is male predominant. Between the age of 50-60 there is no significant different between male and female. Some studies demonstrated that the incidence, prevalence and the severity of this disease is higher in African/Americans.

Incidence

The incidence of Myasthenia gravis is approximately 7-23 new cases per year.[1][2][3][4]

Prevalence

The prevalence of Myasthenia gravis is approximately 70-320 per million and increasing since 20th century.[1][2][4][5]

Age and Gender

The age of onset in Myasthenia gravis follows a bimodal distribution. The early type (before age of 50) is female predominant and the late type (after age of 60) is male predominant. Between the age of 50-60 there is no significant different between male and female.[6]

Race

Some studies demonstrated that the incidence, prevalence and the severity of this disease is higher in African/Americans.[7][8]  

Region

  • The majority of [disease name] cases are reported in [geographical region].
  • [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

References

  1. 1.0 1.1 Carr AS, Cardwell CR, McCarron PO, McConville J (June 2010). "A systematic review of population based epidemiological studies in Myasthenia Gravis". BMC Neurol. 10: 46. doi:10.1186/1471-2377-10-46. PMC 2905354. PMID 20565885.
  2. 2.0 2.1 Heldal AT, Eide GE, Gilhus NE, Romi F (June 2012). "Geographical distribution of a seropositive myasthenia gravis population". Muscle Nerve. 45 (6): 815–9. doi:10.1002/mus.23271. PMID 22581533.
  3. Mombaur B, Lesosky MR, Liebenberg L, Vreede H, Heckmann JM (April 2015). "Incidence of acetylcholine receptor-antibody-positive myasthenia gravis in South Africa". Muscle Nerve. 51 (4): 533–7. doi:10.1002/mus.24348. PMID 25060190.
  4. 4.0 4.1 Breiner A, Widdifield J, Katzberg HD, Barnett C, Bril V, Tu K (January 2016). "Epidemiology of myasthenia gravis in Ontario, Canada". Neuromuscul. Disord. 26 (1): 41–6. doi:10.1016/j.nmd.2015.10.009. PMID 26573434.
  5. Santos E, Coutinho E, Moreira I, Silva AM, Lopes D, Costa H, Silveira F, Nadais G, Morais H, Martins J, Branco MC, Veiga A, Silva RS, Ferreira A, Sousa F, Freijo M, Matos I, André R, Negrão L, Fraga C, Santos M, Sampaio M, Lopes C, Leite MI, Gonçalves G (September 2016). "Epidemiology of myasthenia gravis in Northern Portugal: Frequency estimates and clinical epidemiological distribution of cases". Muscle Nerve. 54 (3): 413–21. doi:10.1002/mus.25068. PMID 26851892.
  6. Alkhawajah NM, Oger J (November 2013). "Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing". Muscle Nerve. 48 (5): 705–10. doi:10.1002/mus.23964. PMID 23893883.
  7. Phillips LH, Torner JC, Anderson MS, Cox GM (October 1992). "The epidemiology of myasthenia gravis in central and western Virginia". Neurology. 42 (10): 1888–93. PMID 1407568.
  8. Oh SJ, Morgan MB, Lu L, Hatanaka Y, Hemmi S, Young A, Claussen GC (March 2009). "Racial differences in myasthenia gravis in Alabama". Muscle Nerve. 39 (3): 328–32. doi:10.1002/mus.21191. PMC 2814330. PMID 19127534.

Template:WH Template:WS